Cargando…
Mucosal bacterial immunotherapy with MV130 highly reduces the need of tonsillectomy in adults with recurrent tonsillitis
Recurrent tonsillitis in adults is a common ENT disease. The current standard treatment is tonsillectomy. However, continuous prophylaxis with antibiotics has been prescribed in order to avoid tonsillectomy. The objective was to evaluate if the bacterial immunotherapy (Bactek MV130) together with th...
Autores principales: | García González, Luis-Amando, Arrutia Díez, Federico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773391/ https://www.ncbi.nlm.nih.gov/pubmed/30779677 http://dx.doi.org/10.1080/21645515.2019.1581537 |
Ejemplares similares
-
Bacterial Mucosal Immunotherapy with MV130 Prevents Recurrent Wheezing in Children: A Randomized, Double-Blind, Placebo-controlled Clinical Trial
por: Nieto, Antonio, et al.
Publicado: (2021) -
Selection of indicators for tonsillectomy in adults with recurrent tonsillitis
por: Kasenõmm, Priit, et al.
Publicado: (2005) -
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity
por: del Fresno, Carlos, et al.
Publicado: (2021) -
Recurrent tonsillitis and parental perceptions of tonsillectomy during the COVID-19 pandemic
por: Heward, Elliot, et al.
Publicado: (2020) -
The Impact of Tobacco Smoking Upon Chronic/Recurrent Tonsillitis and Post Tonsillectomy Bleeding
por: Cinamon, Udi, et al.
Publicado: (2016)